Navigating Ocular Health in the Age of Antibody-drug Conjugates
This article discusses the impact of a new class of targeted drugs for cancer therapy, known as antibody-drug conjugates (ADCs), on ocular health.
- ADCs allow targeted delivery of a highly potent anti-cancer agent to the tumor with limited damage to surrounding healthy cells.
- Each ADC carries its own set of toxicities.
- Mirvetuximab soravtansine-gynx injection 100 mg offers a new option for patients with certain types of ovarian cancer.
- Most mirvetuximab-associated ocular adverse events are low-grade corneal events that are resolvable with supportive care for symptoms and dose modifications when indicated.
- An eye care management plan for mirvetuximab therapy is reflected in US product labeling to include the use of pre-treatment eye drops, ophthalmic monitoring, and dose modifications by the patient’s oncologist.
Epithelial ovarian carcinoma (EOC) is estimated to cause 13,270 deaths in the United States in 2023.
More on Ovarian Cancer